Radiological and histological analysis of synthetic bone grafts in recurring giant cell tumour of bone: a retrospective study

Similar documents
An Assessment of Fate of CHA Blocks Used in the Cystic Lesions of Bone.

Incorporation and biodegradation of hydroxyapatite tricalcium phosphate implanted in large metaphyseal defects An animal study

REASONS TO USE R.T.R.

Inion BioRestore. Bone Graft Substitute. Product Overview

chronos Bone Void Filler. Beta-Tricalcium Phosphate ( β-tcp) bone graft substitute.

Biomaterials Line. MIS Corporation. All Rights Reserved.

BIOACTIVE SYNTHETIC GRAFT

In Vivo Evaluation of BioSphere Bioactive Bone Graft Putty: Improved Bone Formation

Radiology Case Reports. Bone Graft Extruded From an Intramedullary Nail Tract in the Tibia. Penelope J. Galbraith, M.D., and Felix S. Chew, M.D.

Calcium hydroxyapatite ceramic implants in bone tumour surgery

B U I L D S T R O N G B O N E F A S T

botiss dental bone & tissue regeneration biomaterials collacone max Innovative composite matrix socket preservation form-fitting resorbable composite

Bioactive Glass Biphasic β-tcp & HA Granules Alkylene Oxide Polymer Carrier. MEDLINEUNITE Bioactive Bone Graft

Calcium Phosphate Cement

ctive Bone Bonding Bone Regeneration Osteostimulation*

botiss biomaterials bone & tissue regeneration collacone max Innovative composite matrix socket preservation form-fitting resorbable composite

In Vivo Heat-stimulus Triggered Osteogenesis

Comparative Animal Study of OssiMend and Healos 13,14

Evaluation of different grafting materials in three-wall intra-bony defects around dental implants in beagle dogs

PRO-STIM Injectable Inductive Graft TECHNICAL MONOGRAPH

synthetic CANCELLOUS BONE technical monograph Presented by Barbara Blum, Ph.D.

Synthetic and absorbable autograft substitute with osteoinduction

Advice sheet for Surgeons and Radiologists. Radiographic appearance of CERAMENT

ADVANCED BONE GRAFT SYSTEM OVERVIEW

Graftys. Cross-selling. Indications. Comparison. Basic Science. Graftys 415 rue Claude Nicolas Ledoux Aix en Provence Cedex 4

The Outcome of Bone Substitute Wedges in Medial Opening High Tibial Osteotomy

CALCIUM-BASED NEUTRAL AND BIORESORBABLE SELF-SETTING INJECTABLE BONE PUTTY. Ping Luo and Kenneth Trauner* Berkeley Advanced Biomaterials, Inc.

BioVin Collagen Membrane

Bone Grafting and Bone Graft Substitutes. Original Author: James Krieg, MD Revision Author: David Hak, MD Last Revision May 2010

Bone Void Filler. Callos. The Next Generation in Calcium Phosphate Cement A COLSON ASSOCIATE

Regeneration Bone Grafting & Soft Tissue Management

Department of Orthopaedic Surgery NHO, Utsunomiya National Hospital, 2160, Shimo-Okamoto, Utsunomiya City Tochigi, Japan

POWER TO RESTORE WITHOUT LEAVING A TRACE. The only remaining evidence of the trauma

Increased Bone Formation Using a Calcium Sulfate and Calcium Phosphate Composite Graft

BIOACTIVE BASICS. Bioactive materials elicit a controlled action and reaction in the physiological environment.

Accelerated Neutral Atom Beam Processing Improves PEEK In Vivo Osseointegration

Solitary Bone Cyst of the Lunate: A Case Report

HYDROXYAPATITE IN REVISION OF TOTAL HIP REPLACEMENTS WITH MASSIVE ACETABULAR DEFECTS

Ethan M. Braunstein, M.D. 1, Steven A. Goldstein, Ph.D. 2, Janet Ku, M.S. 2, Patrick Smith, M.D. 2, and Larry S. Matthews, M.D. 2

Type of evidence. Design rationale. Economic analysis

chronos Synthetic cancellous bone graft substitute ( -tricalcium phosphate) Remodels Replaced by bone in 6 18 months Easy to use

CELLPLEX TCP SYNTHETIC CANCELLOUS BONE

Technique Guide. chronos Strip. Osteoconductive betatricalcium phosphate ( -TCP) composite.

chronos VIVIFY PREFORMS AND chronos GRANULES BONE VOID FILLER

Frozen recapping laminoplasty: a new technique to treat spinal tumor

Versatile grafting Solutions

BONE TISSUE. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology

Regeneration Bone Grafting & Soft Tissue Management

BONE void FILLER. Beta-tricalcium phosphate ( b-tcp) bone graft substitute. OvERvIEW BROCHURE

A WIDE RANGE OF REGENERATIVE SOLUTIONS

NANOSTIM. Synthetic Bone Paste Resorbable Nanocrystalline Hydroxyapatite

P105 Predictable Bone Grafting for Site Preparation for Implants and Prosthetics Workshop JAMES GRISDALE, DDS THURSDAY, FEBRUARY 26

ARMS. Reconstruction of Large Femur and Tibia Defect with Free Vascularized Fibula Graft and Locking Plate INTRODUCTION.

CASE REPORT COMPLETE BONE REMODELING AFTER CALCAR RECONSTRUCTION WITH METAL WIRE MESH AND IMPACTION BONE GRAFTING: A CASE REPORT

Treatment of the benign lytic lesions of the proximal femur with synthetic bone graft

Unicameral bone cysts are benign, fluid-filled cavities

THE ESSENTIALS IN BONE GRAFTING BRIDGING MEDICAL GAPS

Evaluation of New Biphasic Calcium Phosphate Bone Substitute: Rabbit Femur Defect Model and Preliminary Clinical Results

BEGO BIOMATERIALS When the result counts

Treatment of Distal Radius Bone Defects with Injectable Calcium Sulphate Cement

( ) 2009;28(2):89-94

The injectable, self-setting calcium phosphate bone graft substitute.

Multicentric localized giant cell tumor of the tendon. sheath

Innovative Range of Regenerative Solutions

ORIGINAL ARTICLE Effect of Calcium Phosphate Granules on the Repair of Femoral Bone Defects in Rabbits

Bone formation and osseointegration with titanium implant using granular- and block-type porous hydroxyapatite ceramics (IP-CHA)

CERAMENT BONE VOID FILLER

In search of the optimal material for dental bone grafting

Peggers Super Summaries Basic Sciences Bone

Comblements osseux par céramique phosphocalcique biphasée macroporeuse A propos de 23 cas

Bone ingrowth into two porous ceramics with different pore sizes : An experimental study

Lawrence A. DiDomenico, DPM, FACFAS

Product Information. MIS Corporation. All Rights Reserved.

Allograft Bone and Super Critical Fluid (SCF) Technology

Scientific & Clinical Evidence Jason membrane

Treatment of bone defect with calcium phosphate cement subsequent to tumor curettage in pediatric patients

BonAlive Clinical Cases

Regeneration Bone Grafting & Soft Tissue Management

CASE STUDY: PRO-DENSE Injectable Regenerative Graft Used to Backfill a Bone Cavity Following Resection of a Giant Cell Tumor

More than bone regeneration. A total solution.

Total Hip Arthroplasty around the Inception of the Interface Bioactive Bone Cement Technique

Soft-tissue Recurrence of Giant Cell tumor of Bone Associated with Pulmonary Metastases.

Microparticulate Cortical Allograft: An Alternative to Autograft in the Treatment of Osseous Defects

NEW FIXATION STRATEGIES FOR OSTEOPOROTIC BONE

Graftys Quickset & Graftys HBS use in plateau tibial fracture

AttraX. Portfolio. Surface Drives Performance

The long term fate of the fibula when used as an intraosseous graft

Clinical Experience with a Macroporous Synthetic Bone Substitute (Eurocer ) in the Treatment of the Patients with Bone Defects

Methods Used for Reconstruction in Aggressive Bone Tumours: An Early Experience

Micro-CT evaluation on osteoconductivity of DCPD-coated β-tcp granule using experimental rats

Clinical Policy Title: Bone graft substitutes

Cerasorb M DENTAL. O:\Zulassung\Cerasorb Dental Kanada 2013\Texte\Cerasorb M Dental final IFU docx

VMIC 2017 The Veterinary Medicine International Conference 2017 Volume 2017

Talos -C (HA) and the PEEK-OPTIMA HA Enhanced Technology

MASTERGRAFT Putty. Technical Guide

OssiMend Bone Graft Matrix

Efficiency of Three-Calcium Phosphate Cements in Combination with Bio-Glass for Tibia Bone Recovery in Dogs; Based on Histo-Morphological Evaluations

MARK D. MURPHEY MD, FACR. Physician-in-Chief, AIRP. Chief, Musculoskeletal Imaging

THE NEXT GENERATION OF REGENERATION

SICOT Online Report E057 Accepted April 23th, in Fibula and Rib

Transcription:

Journal of Orthopaedic Surgery 2010;18(1):63-7 Radiological and histological analysis of synthetic bone grafts in recurring giant cell tumour of bone: a retrospective study Hiroyuki Hattori, Hiroaki Matsuoka, Kengo Yamamoto Department of Orthopaedic Surgery, Tokyo Medical University, Tokyo, Japan ABSTRACT Purpose. To review the radiology and histology of synthetic bone grafts resected from patients with recurrent giant cell tumour (GCT) of bone. Methods. 22 patients underwent curettage and grafting for GCT of bone using autogenous cancellous bone mixed with apatite-wollastonite-containing glass ceramic (AWGC), hydroxyapatite (HA), or a mixture of HA and tricalcium phosphate (TCP). Patients were followed up every 3 to 6 months. Three men and 3 women aged 20 to 33 (mean, 27) years developed local recurrence. The mean interval from surgery to recurrence was 35 (range, 12 89) months. Specimens containing the recurring GCT of bone and the surrounding synthetic bone and new bone were evaluated. Results. No complication related to the use of the synthetic bone (such as toxicity, fracture or deformity) occurred. The synthetic bone incorporated well into the surrounding host bone, but was not completely absorbed. HA was more bioactive than AWGC in human bone. HA/TCP were more bioresorbable and osteoconductive in human bone than HA or AWGC. In most areas of AWGC grafts, intervening layers of fibrous connective tissue were seen between the granules and the bone. In most areas of HA grafts, the granules were completely surrounded by viable bone, with bone ingrowth into the pores of the granules, as well as venules and fibrous tissue ingrowth in the pores of portions of the grafts. Conclusion. A mixture of synthetic bone and autogenous cancellous bone is safe and useful for grafting after curettage for GCT of bone. Key words: apatite-wollastonite-containing glass ceramic; bone substitutes; giant cell tumor of bone; hydroxyapatitepolylactide INTRODUCTION Bone grafts can be divided broadly into autografts, allografts, and synthetic grafts. Autografts are osteogenic, osteoinductive, and osteoconductive because they consist of viable cells, matrix proteins, and bony matrix, respectively. 1 Bone defects are usually treated with autografts harvested from the Address correspondence and reprint requests to: Dr Hiroyuki Hattori, Department of Orthopaedic Surgery, Tokyo Medical University Hospital, 6-7-1, Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. E-mail: hiroyuki.hattori@jcom.home.ne.jp

64 H Hattori et al. Journal of Orthopaedic Surgery ilium, but the amount available is limited. Synthetic bones including apatite-wollastonite-containing glass ceramic (AWGC), hydroxyapatite (HA), and tricalcium phosphate (TCP) are biocompatible, bioactive, and osteoconductive. 2 5 They are useful and safe for filling of bone defects after tumour resection. 6 9 Histological analysis of these materials from human samples has been reported. 8 10 We reviewed the radiology and histology of grafted bone resected from patients with recurrent tumours. MATERIALS AND METHODS Between 1995 and 2005, 22 patients underwent curettage and grafting for giant cell tumours (GCT) of bone. The pseudocapsule was dissected circumferentially and excised completely. The entire intra-osseous lesion was curetted, followed by mechanical burring until the normal bone was exposed. The cavity was packed with mixtures of synthetic and autogenous cancellous bones. The synthetic bone used from 1995 to 2000 was AWGC (Cerabone; Nippon Electric Glass, Ohtsu, Japan) with porosity of 70%, pore size of 200 µm, and 900 to 1200ºC sintering temperature. The synthetic bone used from 2001 to 2005 was either pure HA (Apaceram; Asahi Optical, Tokyo, Japan) with porosity of 45%, pore size of 5 to 200 µm, and 1200ºC sintering temperature, or a mixture of HA and TCP (Ceratite; Chugai, Tokyo, Japan) in a ratio of 7:3 with porosity of 35%, pore size of 1 to 15 µm, and 1100ºC sintering temperature. Patients were followed up every 3 to 6 months. Increase in radiographic density of the radiolucent zone surrounding the grafted bone was recorded. Three men and 3 women aged 20 to 33 (mean, 27) years developed local recurrence in the proximal tibia (n=3), distal femur (n=2), and proximal fibula (n=1), which were all confirmed by magnetic resonance imaging. The mean interval from surgery to recurrence was 35 (range, 12 89) months. Three patients had AWGC grafts, 2 had HA grafts, and one had HA/TCP grafts. One patient with recurrence in the proximal fibula underwent en bloc resection without reconstruction. The remaining 5 patients underwent further curettage and grafting with synthetic bone or methylmethacrylate. Specimens containing the recurring GCT of bone and the surrounding synthetic bone and new bone were evaluated using paraffin sections of 3 µm stained with haematoxylin and eosin. RESULTS No complication related to the use of the synthetic bone (such as toxicity, fracture or deformity) occurred. The radiographic density of the grafted bone increased with time. Granules of the synthetic bone had attached to each other at the medullary side and extended cortically. The synthetic bone incorporated well into the surrounding host bone, but was not completely absorbed. Recurring tumours were typically located in the subchondral bone near the cortical window, and partially intruded into the absorbed synthetic bone (Fig. 1). Radiologically, most areas of AWGC grafts were hypointense, and granules were distinguishable as void signals on both T1- and T2-weighted images. Figure 1 Postoperative radiographs of the right proximal tibia in a 33-year-old woman: a clear margin between the bone and the hydroxyapatite granules immediately after surgery; the hydroxyapatite graft is homogenously incorporated 6 months later, with a diminishing margin; and (c) increased lucency at the superior edge of the hydroxyapatite graft, with evidence of infiltrating recurrent tumour.

Vol. 18 No. 1, April 2010 Synthetic bone grafts in recurring GCT of bone 65 Figure 2 The left distal femur in a 30-year-old man 27 months after surgery: the granules of the apatite-wollastonitecontaining glass ceramic graft are homogenously incorporated; a hypointense signal throughout the graft site in a T1- weighted image; (c) a hyperintense signal surrounding speckle void signals in a T2-weighted image. Figure 3 The right distal femur of a 30-year-old man 24 months after surgery: the granules of hydroxyapatite graft are homogenously incorporated; the centre of the graft is isointense and its surrounding is hypointense in a T1-weighted image; (c) the centre of the graft is hyperintense and its surrounding is hypointense in a T2-weighted image. The surrounding areas were isointense on T1- and hyperintense on T2-weighted images (Fig. 2). The centres of HA-containing grafts were isointense on T1- and hyperintense on T2-weighted images. The circumference was hypointense on both T1- and T2-weighted images, and the granules were indistinguishable (Fig. 3). Histologically, most areas of AWGC grafts showed intervening layers of fibrous connective tissue between the granules and the bone. Only a small portion of the graft interface was the newly formed lamellar with osteoblasts attached to the granules (Fig. 4). In most areas of HA grafts, however, the granules were completely surrounded by viable bone, with bone ingrowth into the pores of the granules, as well as venules, and fibrous tissue ingrowth into the pores of portions of the grafts (Fig. 5). Recurring tumour cells were in direct contact with the synthetic bone and extended into the pores. Large numbers of multinucleated giant cells surrounded the granules of synthetic bone (Fig. 6). DISCUSSION This retrospective study was not a comparative study of AWGC and HA. In patients with HA-containing grafts, the formation of osteons in the pores was evident, as was the ingrowth of the venules and fibrous tissue into the pores. In a study in which a porous HA

66 Journal of Orthopaedic Surgery H Hattori et al. Figure 4 Photomicrographs of the apatite-wollastonite-containing glass ceramic graft 12 months after surgery: an intervening layer of fibrous connective tissue between granules and the bone (H&E, x40); and newly formed lamellar bone containing osteoblasts is partially attached to the granule (H&E, x400). Figure 5 Photomicrographs of the hydroxyapatite graft 27 months after surgery: the granules are in direct contact to the viable bone (H&E, x80); and fibrous tissue is partially surrounded by granules, with the ingrowth of venules into the pores (H&E, x80). (c) Figure 6 Photomicrographs of recurring tumours (H&E, x80): tumour cells surround the granules and extend into the pores of the apatite-wollastonite-containing glass ceramic graft, and hydroxyapatite graft. Multinucleated giant cells surround the granules of the (c) hydroxyapatite and tricalcium phosphate mixture graft.

Vol. 18 No. 1, April 2010 Synthetic bone grafts in recurring GCT of bone 67 block was placed into the proximal tibial metaphysis of dogs, 3 at 12 months 66.5% of the implant surface was covered with bone ingrowth. AWGC was less bioactive than HA in human bone. Although AWGC was shown to contact newly formed bone directly in experimental animals, 2,4 in our study there were intervening layers of fibrous connective tissue between the granules and the bone, with different signal intensity from the bone trabeculae. HA/TCP were more bioresorbable and osteoconductive in human bone than HA or AWGC. Resorption of synthetic bone involves a solution-mediated process (the implant dissolves in physiologic solutions) and a cell-mediated process (phagocytosis). 11 Partial dissolution of the synthetic bone in the former process initiates the accumulation of phagocytic cells (macrophages or osteoclasts), which play a major role in resorption. In our study, accumulation of osteoclasts around the graft was not identified, but multinucleated giant cells were noted to surround the granules of the HA/TCP graft only. This suggests that HA/ TCP has a more aggressive cell-mediated process of resorption than HA or AWGC. Additionally, Cathepsin K, a cysteine protease, is expressed in both osteoclasts (responsible for the degradation of collagen matrix during bone remodelling) and multinucleated giant cells (responsible for osteolysis) in GCTs. 12 A variety of synthetic bone grafts have been used to promote new bone formation and structural support. They achieve mechanical strength immediately after grafting by stimulating osteoconduction. Most synthetic bones provide an osteoconductive lattice upon which host osteogenesis can take place. Autogenous cancellous bone should be added to provide osteoinductivity. Therefore, a mixture of synthetic bone and autogenous cancellous bone is preferable. REFERENCES 1. Bauer TW, Muschler GF. Bone graft materials. An overview of the basic science. Clin Orthop Relat Res 2000;371:10 27. 2. Fujita H, Iida H, Ido K, Matsuda Y, Oka M, Nakamura T. Porous apatite-wollastonite glass-ceramic as an intramedullary plug. J Bone Joint Surg Br 2000;82:614 8. 3. Holmes RE, Bucholz RW, Mooney V. Porous hydroxyapatite as a bone-graft substitute in metaphyseal defects. A histometric study. J Bone Joint Surg Am 1986;68:904 11. 4. Teramoto H, Kawai A, Sugihara S, Yoshida A, Inoue H. Resorption of apatite-wollastonite containing glass-ceramic and beta-tricalcium phosphate in vivo. Acta Med Okayama 2005;59:201 7. 5. Walsh WR, Vizesi F, Michael D, Auld J, Langdown A, Oliver R, et al. Beta-TCP bone graft substitutes in a bilateral rabbit tibial defect model. Biomaterials 2008;29:266 71. 6. Matsumine A, Myoui A, Kusuzaki K, Araki N, Seto M, Yoshikawa H, et al. Calcium hydroxyapatite ceramic implants in bone tumour surgery. A long-term follow-up study. J Bone Joint Surg Br 2004;86:719 25. 7. Ogose A, Hotta T, Kawashima H, Kondo N, Gu W, Kamura T, et al. Comparison of hydroxyapatite and beta tricalcium phosphate as bone substitutes after excision of bone tumors. J Biomed Mater Res B Appl Biomater 2005;72:94 101. 8. Uchida A, Araki N, Shinto Y, Yoshikawa H, Kurisaki E, Ono K. The use of calcium hydroxyapatite ceramic in bone tumour surgery. J Bone Joint Surg Br 1990;72:298 302. 9. Yamamoto T, Onga T, Marui T, Mizuno K. Use of hydroxyapatite to fill cavities after excision of benign bone tumours. Clinical results. J Bone Joint Surg Br 2000;82:1117 20. 10. Tachibana Y, Ninomiya S, Kim YT, Sekikawa M. Tissue response to porous hydroxyapatite ceramic in the human femoral head. J Orthop Sci 2003;8:549 53. 11. Jarcho M. Calcium phosphate ceramics as hard tissue prosthetics. Clin Orthop Relat Res 1981;157:259 78. 12. Lindeman JH, Hanemaaijer R, Mulder A, Dijkstra PD, Szuhai K, Bromme D, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593 600.